Navigation Links
Vaccine first to show improved survival rates for metastatic melanoma
Date:6/3/2011

(CHICAGO) For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival.

The findings of the study were published in the June 2 issue of New England Journal of Medicine. This marks the first vaccine study in the disease and one of the first in all cancers to show clinical benefit in a randomized Phase III clinical trial.

"This is the first time that a vaccine has shown benefit in the treatment of patients with metastatic melanoma. The trial is an early example of success with a cancer vaccine," said Dr. Howard Kaufman, director for the Rush University Cancer Center and study co-investigator.

"If we can use the body's own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue," said Kaufman, who is also an associate dean of Rush Medical College and a professor in the departments of general surgery, internal medicine and immunology and microbiology at Rush University.

Therapeutic cancer vaccines, unlike typical vaccines that prevent infections, are meant to jump-start the immune system to help it battle existing tumors.

Rush was one of 21 centers in the U.S. participating in the trial. Researchers randomly assigned 185 patients with metastatic melanoma to either a combination of the peptide vaccine, which is a small portion of protein that is present on the surface of the melanoma cancer cells, and Interleukin-2, a drug that activates the immune system, or a high dose of Interleukin-2 alone.

The peptide vaccine, known as gp100:209-217 (200M), works by stimulating the patient's T-cells, which is known for controlling immune responses. The injection primes the immune system to recognize the protein and activates the body's cytotoxic T-cells to
'/>"/>

Contact: Deb Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Study finds vaccine extends recurrent GBM survival rates by 2 to 3 times
2. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
3. Therapeutic melanoma vaccine improves response rate, progression-free survival
4. Melanoma Vaccine Shows Promise in Trial
5. Vaccine increases disease-free survival for follicular lymphoma patients
6. Black Americans With Lupus Have Better Response to Flu Vaccine
7. African-Americans with SLE more responsive to flu vaccine than patients of European descent
8. Toward a vaccine for methamphetamine abuse
9. Model developed to improve combination vaccine accessibility worldwide
10. Rino Rappuoli honored for his work in vaccines and vaccinology
11. Insight into HIV immunity may lead to vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers allows users to clarify, edit and delete any message including ones already ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source of authentic ... Grand Garden Arena. Fans of every genre of music will have an act they ... first day of the festival, the following artists will perform: Sam Smith, Coldplay, Kenny ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will emanate ... Football League’s biggest day each year is the Super Bowl. In the two weeks that ... place from the host venue. The 2016 Super Bowl game will mark the 50th time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted ... in predictive health analytics , Jvion continues to disrupt the predictive analytic ... software that targets patient and population level illness to drive prevention and better ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator for ... applicator in the United States as an upgrade to the CoolSmooth applicator cleared by ... required a 2 hour treatment time. The new CoolSmooth Pro reduces the treatment ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Currently lie detection methods use heart activity, but now the ... detection reports the online edition of New Scientist. // ... Texas found that the heart is unreliable as it's affected ... as hormones, ,"But the gut has a mind of its ...
... polio. Only 30 cases have been reported till mid September this ... ,In the whole of 2004, there were only ... is expected to announce by the end of this year or ... ,Among the 30 cases, 16 have been reported from Uttar Pradesh, ...
... research in United Kingdom as part of ?145m package ... worldwide. Bill Gates along with his Melinda Gates Foundation ... malaria eradication over the next five years. Mr. Gates ... of AIDS and cancer, while malaria, which kills millions ...
... Mizoram the border state of the country has strictly ... its neighboring country Myanmar to combat the ongoing was ... a long (404-kms) international border with Myanmar and there ... Mr. C Sangnghina, The Director of State Animal Husbandry ...
... recent study was conducted to investigate the association among ... factors. The results indicate that diabetic women have a ... there is no relationship between osteoporosis and cardiovascular risk ... far been believed that Type II diabetics have bone ...
... A diet with high fat and sugar induces abnormalities in ... cells in the liver, according to a study of mice ... ,The study, published in the Oct. issue of the ... not only gained more weight, but also developed fatty livers ...
Cached Medicine News:Health News:Bill Gates to Fund ?28m for Malaria researc 2Health News:Diabetic Type II Women Have Elevated Bone Density Mass 2
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... , July 31, 2015 ... 2015 market research report that provides an overview ... using data sourced from in-house databases, secondary and ... and needles market products pipeline spread across 124 ... with 73 tables and 5 figures is now ...
(Date:7/31/2015)... Quietly, sedately, Morocco,s pharmaceutical sector is shining. ... is strong, with a well-developed base of local producers ... One place where the quality of Moroccan pharma ... quietly become the second largest African exporter of drugs ... Moroccan pharma companies have been making inroads as exporters ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... DUBLIN, June 28, 2011 ,   ... SHPGY ), the global specialty,biopharmaceutical company, announces that following ... the,waiting period under the Hart-Scott-Rodino Antitrust Improvements,Act of 1976, ... on May 17, 2011, has been completed. ...
... EXTON, Pa., June 28, 2011 Morphotek®, Inc., a ... commenced a multi-center phase II study of farletuzumab in ... lung cancer (NSCLC). The study will evaluate farletuzumab, a ... with the physician,s choice of one of three standard ...
Cached Medicine Technology:Shire Completes Acquisition of Advanced BioHealing, Inc. 2Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer 2Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer 3Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: